Trump blasts Big Pharma again — “somebody’s getting very rich” — and promises drug price legislation
On Monday Eli Lilly CEO Dave Ricks outlined his company’s case that their drug prices are not spinning out of control. In a lengthy report he asserted that discounts on drug prices to pharma benefit managers has grown from 28% in 2012 to an average of 50% last year. And while list prices grew 14% last year, net prices actually grew by only 2.4%.
That position reflected a growing effort on Big Pharma’s part — a defensive reaction that also includes two other US-based pharma giants, Merck and J&J — to defend itself against growing pressure from the Trump administration to rein in drug prices.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.